Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action

Patients with diabetes mellitus (DM) type 1 and 2 are at a higher risk of cognitive decline and dementia; however, the underlying pathology is poorly understood. Kynurenic acid (KYNA), endogenous kynurenine metabolite, displays pleiotropic effects, including a blockade of glutamatergic and cholinerg...

Full description

Saved in:
Bibliographic Details
Main Authors: Iwona Chmiel-Perzyńska, Adam Perzyński, Bartosz Olajossy, Paulina Gil-Kulik, Janusz Kocki, Ewa M. Urbańska
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2019/4957879
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850106884304928768
author Iwona Chmiel-Perzyńska
Adam Perzyński
Bartosz Olajossy
Paulina Gil-Kulik
Janusz Kocki
Ewa M. Urbańska
author_facet Iwona Chmiel-Perzyńska
Adam Perzyński
Bartosz Olajossy
Paulina Gil-Kulik
Janusz Kocki
Ewa M. Urbańska
author_sort Iwona Chmiel-Perzyńska
collection DOAJ
description Patients with diabetes mellitus (DM) type 1 and 2 are at a higher risk of cognitive decline and dementia; however, the underlying pathology is poorly understood. Kynurenic acid (KYNA), endogenous kynurenine metabolite, displays pleiotropic effects, including a blockade of glutamatergic and cholinergic receptors. Apart from well-known glial origin, kynurenic acid is robustly synthesized in the endothelium and its serum levels correlate with homocysteine, a risk factor for cognitive decline. Studies in an experimental DM model suggest that a selective, hippocampal increase of the kynurenic acid level may be an important factor contributing to diabetes-related cognitive impairment. The aim of this study was to assess the effects of chronic, four-week administration of losartan, angiotensin receptor blocker (ARB), on the brain KYNA in diabetic rats. Chromatographic and rt-PCR techniques were used to measure the level of KYNA and the expression of genes encoding kynurenine aminotransferases, KYNA biosynthetic enzymes, in the hippocampi of rats with streptozotocin-induced DM, treated with losartan. The effect of losartan on KYNA synthesis de novo was also evaluated in vitro, in brain cortical slices. The hippocampal increase of KYNA content occurred in diabetic rats treated and nontreated with insulin. Losartan did not affect KYNA levels when administered per se to naïve or diabetic animals but normalized KYNA content in diabetic rats receiving concomitantly insulin. The expression of CCBL1 (kat 1), AADAT (kat 2), and KAT3 (kat 3) genes did not differ between analyzed groups. Low concentrations of losartan did not affect KYNA production in vitro. The neuroprotective effect of ARBs in diabetic individuals may be, at least partially, linked to modulation of KYNA metabolism. The ability of ARB to modulate synthesis of KYNA in diabetic brain does not seem to result from changed expression of genes encoding KATs. We propose possible involvement of angiotensin AT4 receptors in the observed action of losartan.
format Article
id doaj-art-4d88eeb0b9a74e9e9a161ba90f4d1d92
institution OA Journals
issn 2314-6745
2314-6753
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Journal of Diabetes Research
spelling doaj-art-4d88eeb0b9a74e9e9a161ba90f4d1d922025-08-20T02:38:43ZengWileyJournal of Diabetes Research2314-67452314-67532019-01-01201910.1155/2019/49578794957879Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan ActionIwona Chmiel-Perzyńska0Adam Perzyński1Bartosz Olajossy2Paulina Gil-Kulik3Janusz Kocki4Ewa M. Urbańska5Department of Experimental and Clinical Pharmacology, Medical University in Lublin, PolandII Department of Psychiatry and Psychiatry Rehabilitation, Medical University in Lublin, PolandInternal Medicine and Cardiology Clinic, 1st Military Clinical Hospital in Lublin, PolandDepartment of Clinical Genetics, Medical University in Lublin, PolandDepartment of Clinical Genetics, Medical University in Lublin, PolandDepartment of Experimental and Clinical Pharmacology, Medical University in Lublin, PolandPatients with diabetes mellitus (DM) type 1 and 2 are at a higher risk of cognitive decline and dementia; however, the underlying pathology is poorly understood. Kynurenic acid (KYNA), endogenous kynurenine metabolite, displays pleiotropic effects, including a blockade of glutamatergic and cholinergic receptors. Apart from well-known glial origin, kynurenic acid is robustly synthesized in the endothelium and its serum levels correlate with homocysteine, a risk factor for cognitive decline. Studies in an experimental DM model suggest that a selective, hippocampal increase of the kynurenic acid level may be an important factor contributing to diabetes-related cognitive impairment. The aim of this study was to assess the effects of chronic, four-week administration of losartan, angiotensin receptor blocker (ARB), on the brain KYNA in diabetic rats. Chromatographic and rt-PCR techniques were used to measure the level of KYNA and the expression of genes encoding kynurenine aminotransferases, KYNA biosynthetic enzymes, in the hippocampi of rats with streptozotocin-induced DM, treated with losartan. The effect of losartan on KYNA synthesis de novo was also evaluated in vitro, in brain cortical slices. The hippocampal increase of KYNA content occurred in diabetic rats treated and nontreated with insulin. Losartan did not affect KYNA levels when administered per se to naïve or diabetic animals but normalized KYNA content in diabetic rats receiving concomitantly insulin. The expression of CCBL1 (kat 1), AADAT (kat 2), and KAT3 (kat 3) genes did not differ between analyzed groups. Low concentrations of losartan did not affect KYNA production in vitro. The neuroprotective effect of ARBs in diabetic individuals may be, at least partially, linked to modulation of KYNA metabolism. The ability of ARB to modulate synthesis of KYNA in diabetic brain does not seem to result from changed expression of genes encoding KATs. We propose possible involvement of angiotensin AT4 receptors in the observed action of losartan.http://dx.doi.org/10.1155/2019/4957879
spellingShingle Iwona Chmiel-Perzyńska
Adam Perzyński
Bartosz Olajossy
Paulina Gil-Kulik
Janusz Kocki
Ewa M. Urbańska
Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action
Journal of Diabetes Research
title Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action
title_full Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action
title_fullStr Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action
title_full_unstemmed Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action
title_short Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action
title_sort losartan reverses hippocampal increase of kynurenic acid in type 1 diabetic rats a novel procognitive aspect of sartan action
url http://dx.doi.org/10.1155/2019/4957879
work_keys_str_mv AT iwonachmielperzynska losartanreverseshippocampalincreaseofkynurenicacidintype1diabeticratsanovelprocognitiveaspectofsartanaction
AT adamperzynski losartanreverseshippocampalincreaseofkynurenicacidintype1diabeticratsanovelprocognitiveaspectofsartanaction
AT bartoszolajossy losartanreverseshippocampalincreaseofkynurenicacidintype1diabeticratsanovelprocognitiveaspectofsartanaction
AT paulinagilkulik losartanreverseshippocampalincreaseofkynurenicacidintype1diabeticratsanovelprocognitiveaspectofsartanaction
AT januszkocki losartanreverseshippocampalincreaseofkynurenicacidintype1diabeticratsanovelprocognitiveaspectofsartanaction
AT ewamurbanska losartanreverseshippocampalincreaseofkynurenicacidintype1diabeticratsanovelprocognitiveaspectofsartanaction